Patents by Inventor Wolfgang Halfbrodt

Wolfgang Halfbrodt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 14-.alpha., 17-.alpha.-C.sub.2 bridged norprogesterone derivatives
    Patent number: 6147065
    Abstract: Described are 14,17-C.sub.2 -bridged steroids of the formula (I) defined in the specification. The compounds are available, even after peroral administration, with high gestagenic action and are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: November 14, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Klaus Schollkopf, Wolfgang Halfbrodt, Joachim Kuhnke, Wolfgang Schwede, Karl-Heinrich Fritzemeier, Rolf Krattenmacher, Hans-Peter Muhn
  • 14-.alpha.,17-.alpha.-C.sub.2 -bridged norprogesterone derivatives
    Patent number: 5973172
    Abstract: The invention describes 14,17-C.sub.2 -bridged steroids of general formula (I), ##STR1## wherein the various R groups are as defined in the specification, and wherein said steroids are in contrast, with the disclaimed compound, the new compounds are available even after peroral administration with high gestagenic action and are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: October 26, 1999
    Assignee: Schering Akitengesellschaft
    Inventors: Klaus Schollkopf, Wolfgang Halfbrodt, Joachim Kuhnke, Wolfgang Schwede, Karl-Heinrich Fritzemeier, Rolf Krattenmacher, Hans-Peter Muhn
  • 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivatives
    Patent number: 5827842
    Abstract: The invention describes 14,17-C.sub.2 -bridged steroids of general formula (I), ##STR1## wherein the various R groups are as defined in the specification, and wherein said steroids are, in contrast with the disclaimed compound 14,17-ethano-19-norpregn-4-ene-3,20-dione bioavailable even after peroral administration with high gestagenic action and are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: December 26, 1995
    Date of Patent: October 27, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Klaus Schollkopf, Wolfgang Halfbrodt, Joachim Kuhnke, Wolfgang Schwede, Karl-Heinrich Fritzemeier, Rolf Krattenmacher, Hans-Peter Muhn
  • Progestationally active 19,11-bridged 4-estrenes
    Patent number: 5703066
    Abstract: In this invention, the new etheno- and ethano-19,11-bridged 4-estrenes of general formula I ##STR1## are described, in whichW, R.sup.1, R.sup.2, R.sup.6a, R.sup.6b, R.sup.7, R.sup.14, R.sup.15, R.sup.16, R.sup.11, R.sup.11' and R.sup.19 have the meaning indicated in the description, as well as a process for their production.The new compounds have strong progestational activity and are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 30, 1997
    Assignee: Schering Aktiengesellschaft
    Inventors: Eckhard Ottow, Wolfgang Schwede, Wolfgang Halfbrodt, Karl-Heinrich Fritzemeier, Rolf Krattenmacher
  • Progestationally active 19,11-bridged 4-estrenes
    Patent number: 5523298
    Abstract: In this invention, the new etheno- and ethano-19,11-bridged 4-estrenes of general formula I ##STR1## are described, in which W, R.sup.1, R.sup.2, R.sup.6a, R.sup.6b, R.sup.7, R.sup.14, R.sup.15, R.sup.16, R.sup.11, R.sup.11' and R.sup.19 have the meaning indicated in the description, as well as a process for their production.The new compounds have strong progestational activity and are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: October 13, 1993
    Date of Patent: June 4, 1996
    Assignee: Schering Aktiengesellschaft
    Inventors: Eckhard Ottow, Wolfgang Schwede, Wolfgang Halfbrodt, Karl-Heinrich Fritzemeier, Rolf Krattenmacher